SEC Filing Details

Document Details

Form

Filing Date

Mar 19, 2026

Document Date

Mar 17, 2026

Form Description

Statement of changes in beneficial ownership of securities

Filing Group

3,4,5

Company

MaxCyte Inc

Issuer

MAXCYTE, INC.

Filer

Swirsky Douglas J

Filing Formats

View HTML

Download PDF

Download DOC

Download XLS

Electroporation Systems

ATx

From small to medium static Electroporation.

STx

Transfect up to 20 billion cells with scalable static or Flow Electroporation®.

GTx

Transfect up to 20 billion cells with our clinically validated and cGMP compliant Flow Electroporation®.

VLx

For gram scale protein production.

Our Electroporation Technology

Consumables

Processing Assemblies

Achieve the desired scale and throughput with a range of consumable devices.

Reagents & Supporting Products

Complement your workflow with our flexible electroporation buffer formats and accessories.

Applications

Cell Therapy

Discover scalable engineering to enable safe and potent cell therapies.

Gene Editing

Navigate the complexities of genome engineering with highly efficient delivery.

Protein & Antibody Production

Accelerate biotherapeutic development with transient expression for gram-scale protein production.

Cell Based Assays

Produce assay-ready cells faster with scalable electroporation.

Viral Vector

Transfect adherent or suspension cells to produce a variety of viral vectors.

Vaccine Development

Innovate vaccine research with our adaptable platform for production of recombinant proteins, virus-like particles.

Industries

Cell & Gene Therapy

Partnering with developers to accelerate development and scale cell therapy programs toward clinical success.

Discovery & Translational Research

Accelerating breakthrough discoveries with high-efficiency, reproducible electroporation across cell types.

Bioprocessing

Enabling efficient, reproducible transfection in virtually any cell type for high-yield transient expression and rapid cell line development.